Comorbidities in rheumatoid arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 21, Issue 5, 2007, Pages 885-906

  Michaud, Kaleb ^a,b   Wolfe, Frederick ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

anti TNF therapy; cardiovascular disease; comorbid condition; comorbidity; comorbidity index; infection; malignancy; outcomes; rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CORTISONE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; VITAMIN D;

ANEMIA; ARTHRALGIA; AUTOIMMUNE DISEASE; BODY FAT DISTRIBUTION; BREAST CANCER; BREAST CARCINOGENESIS; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON CANCER; COMORBIDITY; CONGESTIVE HEART FAILURE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEPRESSION; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DIVERTICULOSIS; DRUG FATALITY; DRUG WITHDRAWAL; ENTEROPATHY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HEART INFARCTION; HERPES ZOSTER; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; INTESTINAL BLEEDING; JOINT SWELLING; LOW DRUG DOSE; LUNG CANCER; LUNG DISEASE; LUNG TOXICITY; LYMPHOMA; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL VASCULAR DISEASE; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN BRUISING; SKIN CANCER; SKIN DISEASE; SKIN TOXICITY; THORAX RADIOGRAPHY; TUBERCULOSIS; WEIGHT GAIN;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; COMORBIDITY; HUMANS; INCIDENCE; NEOPLASMS;

EID: 34548510858     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2007.06.002     Document Type: Review

References (171)

1. Wolfe F., and Michaud K. Data collection, maintenance, analysis for rheumatic disease research. Rheumatic Diseases Clinics of North America 30 4 (2004) 753-768 vi
2. Hernández-Cruz B., Carmona L., Dolores Ruiz-Montesinos M., et al. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. Arthritis and Rheumatism 55 5 (2006) 751-756
3. Marra C.A., Esdaile J.M., Guh D., et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Medical Care 42 11 (2004) 1125-1131
4. Crowson C.S., Nicola P.J., Kremers H.M., et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?. Arthritis and Rheumatism 52 10 (2005) 3039-3044
5. Charlson M., Pompei P., Ales K., and MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 40 5 (1987) 373-383
6. Kaplan M.H., and Feinstein A.R. The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus. Journal of Chronic Diseases 27 7-8 (1974) 387-404
7. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. Journal of Clinical Epidemiology 45 2 (1992) 197-203
8. Greenfield S., Apolone G., McNeil B.J., and Cleary P.D. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Medical Care 31 2 (1993) 141-154
9. Miller M.D., Paradis C.F., Houck P.R., et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Research 41 3 (1992) 237-248
10. Groll D.L., To T., Bombardier C., and Wright J.G. The development of a comorbidity index with physical function as the outcome. Journal of Clinical Epidemiology 58 6 (2005) 595-602
11. Nicola P.J., Crowson C.S., Maradit-Kremers H., et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis and Rheumatism 54 1 (2006) 60-67
12. Goodson N., Marks J., Lunt M., and Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Annals of the Rheumatic Diseases 64 11 (2005) 1595-1601
13. Van Doornum S., Brand C., King B., and Sundararajan V. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis and Rheumatism 54 7 (2006) 2061-2068
14. Sodergren A., Stegmayr B., Lundberg V., et al. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases 66 2 (2007) 263-266
15. Solomon D.H., Goodson N.J., Katz J.N., et al. Patterns of cardiovascular risk in rheumatoid arthritis. Annals of the Rheumatic Diseases 65 12 (2006) 1608-1612
16. Wolfe F., and Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, the effect of anti-tumor necrosis factor therapy. American Journal of Medicine 116 5 (2004) 305-311
17. Suissa S., Bernatsky S., and Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis and Rheumatism 55 4 (2006) 531-536
18. Fischer L.M., Schlienger R.G., Matter C., et al. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. American Journal of Cardiology 93 2 (2004) 198-200
19. Watson D.J., Rhodes T., and Guess H.A. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. The Journal of Rheumatology 30 6 (2003) 1196-1202
20. Bleumink G.S., Knetsch A.M., Sturkenboom M.C., et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. European Heart Journal 25 18 (2004) 1614-1619
21. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 24 (2002) 3068-3072
22. Levy D., Kenchaiah S., Larson M.G., et al. Long-term trends in the incidence of and survival with heart failure. The New England Journal Medicine 347 18 (2002) 1397-1402
23. Nicola P.J., Maradit-Kremers H., Roger V.L., et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis and Rheumatism 52 2 (2005) 412-420
24. Bernatsky S., Hudson M., and Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44 5 (2005) 677-680
25. Han C., Robinson Jr. D.W., Hackett M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis. The Journal of Rheumatology 33 11 (2006) 2167-2172
26. Wolfe F., Freundlich B., and Straus W.L. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. The Journal of Rheumatology 30 1 (2003) 36-40
27. Solomon D.H., Karlson E.W., Rimm E.B., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107 9 (2003) 1303-1307
28. Turesson C., Jarenros A., and Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Annals of the Rheumatic Diseases 63 8 (2004) 952-955
29. Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis and Rheumatism 52 3 (2005) 722-732
30. Sany J., Bourgeois P., Saraux A., et al. Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists. Annals of the Rheumatic Diseases 63 10 (2004) 1235-1240
31. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 9313 (2002) 1173-1177
32. Jacobsson L.T., Turesson C., Nilsson J.A., et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 66 5 (2007) 670-675
33. Holman A.J. Considering cardiovascular mortality in patients with rheumatoid arthritis from a different perspective: a role for autonomic dysregulation and obstructive sleep apnea. The Journal of Rheumatology 34 4 (2007) 671-673
34. Carmona L., Descalzo M.A., Perez-Pampin E., et al. All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with TNF antagonists. Annals of the Rheumatic Diseases (2007)
35. Watson K.D., Hyrich K.L., Dixon W.G., et al. All cause mortality is not increased following the use of Anti-TNF Agents in patients with rheumatoid arthritis: results from a nation-wide prospective study. Arthritis and Rheumatism 52 9 (supplement) (2005) S229
36. Kaplan M.J. Cardiovascular disease in rheumatoid arthritis. Current Opinion In Rheumatology 18 3 (2006) 289-297
37. Mikuls T.R. Co-morbidity in rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology 17 5 (2003) 729-752
38. Giles J.T., Fernandes V., Lima J.A., and Bathon J.M. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Research & Therapy 7 5 (2005) 195-207
39. Mellemkjaer L., Linet M.S., Gridley G., et al. Rheumatoid arthritis and cancer risk. European Journal of Cancer 32A 10 (1996) 1753-1757
40. Askling J., Fored C.M., Brandt L., et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Annals of the Rheumatic Diseases 64 10 (2005) 1421-1426
41. Askling J., Fored C.M., Baecklund E., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Annals of the Rheumatic Diseases 64 10 (2005) 1414-1420
42. Wolfe F., and Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation. Arthritis and Rheumatism 56 5 (2007) 1433-1439
43. Klareskog L., Stolt P., Lundberg K., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis and Rheumatism 54 1 (2006) 38-46
44. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis and Rheumatism 54 3 (2006) 692-701
45. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non_Hodgkin's lymphoma in rheumatoid arthritis. Arthritis and Rheumatism 41 supplement (1998) S188
46. Baecklund E., Ekbom A., Sparen P., et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ (Clinical Research Ed.) 317 7152 (1998) 180-181
47. Thomas E., Symmons D.P., Brewster D.H., et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, other rheumatic conditions: a 20 year followup study. The Journal of Rheumatology 30 5 (2003) 958-965
48. Karlson E.W., Lee I.M., Cook N.R., et al. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis and Rheumatism 42 5 (1999) 910-917
49. Uhlig T., Hagen K.B., and Kvien T.K. Current tobacco smoking, formal education, the risk of rheumatoid arthritis. The Journal of Rheumatology 26 1 (1999) 47-54
50. Symmons D.P., Bankhead C.R., Harrison B.J., et al. Blood transfusion, smoking, obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis and Rheumatism 40 11 (1997) 1955-1961
51. Vessey M.P., Villard-Mackintosh L., and Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception 35 5 (1987) 457-464
52. Hernandez Avila M., Liang M.H., Willett W.C., et al. Reproductive factors, smoking, the risk for rheumatoid arthritis. Epidemiology (Cambridge, Mass.) 1 4 (1990) 285-291
53. Heliovaara M., Aho K., Aromaa A., et al. Smoking and risk of rheumatoid arthritis. The Journal of Rheumatology 20 11 (1993) 1830-1835
54. Voigt L.F., Deng Q., and Weiss N.S. Recency, duration, progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes & Control 5 3 (1994) 227-233
55. Silman A.J., Newman J., and MacGregor A.J. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis and Rheumatism 39 5 (1996) 732-735
56. Wolfe F. The effect of smoking on clinical, laboratory, radiographic status in rheumatoid arthritis. The Journal of Rheumatology 27 3 (2000) 630-637
57. Hutchinson D., Shepstone L., Moots R., et al. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Annals of the Rheumatic Diseases 60 3 (2001) 223-227
58. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis and Rheumatism 37 4 (1994) 481-494
59. Dawson J.K., Fewins H.E., Desmond J., et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, pulmonary function tests. Thorax 56 8 (2001) 622-627
60. Fewins H.E., McGowan I., Whitehouse G.H., et al. High definition computed tomography in rheumatoid arthritis associated pulmonary disease. British Journal of Rheumatology 30 3 (1991) 214-216
61. Gabbay E., Tarala R., Will R., et al. Interstitial lung disease in recent onset rheumatoid arthritis. American Journal of Respiratory and Critical Care Medicine 156 2 Pt 1 (1997) 528-535
62. McDonagh J., Greaves M., Wright A.R., et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. British Journal of Rheumatology 33 2 (1994) 118-122
63. Cortet B., Perez T., Roux N., et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 56 10 (1997) 596-600
64. Hubbard R., Venn A., Lewis S., and Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. American Journal of Respiratory and Critical Care Medicine 161 1 (2000) 5-8
65. Artinian V., and Kvale P.A. Cancer and interstitial lung disease. Current Opinion in Pulmonary Medicine 10 5 (2004) 425-434
66. Geborek P., Bladström A., Turesson C., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Annals of the Rheumatic Diseases 64 5 (2005) 699-703
67. Franklin J., Lunt M., Bunn D., et al. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Annals of the Rheumatic Diseases 65 5 (2006) 617-622
68. Symmons D.P. Lymphoma and rheumatoid arthritis-again. Rheumatology (Oxford) 46 1 (2007) 1-2
69. Setoguchi S., Solomon D.H., Weinblatt M.E., et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis and Rheumatism 54 9 (2006) 2757-2764
70. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. The Journal of the American Medical Association 295 19 (2006) 2275-2285
71. Madhusudan S., Foster M., Muthuramalingam S.R., et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clinical Cancer Research 10 19 (2004) 6528-6534
72. James W.H. Hypothesis: gonadal hormones act as confounders in epidemiological studies of the associations between some behavioural risk factors and some pathological conditions. Journal of Theoretical Biology 209 1 (2001) 97-102
73. Thomas E., Brewster D.H., Black R.J., and Macfarlane G.J. Risk of malignancy among patients with rheumatic conditions. International Journal of Cancer 88 3 (2000) 497-502
74. Kauppi M., Pukkala E., and Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 14 5 (1996) 551-553
75. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a Large U.S. Observational Study. Arthritis and Rheumatism in press.
76. Logan R.F., Little J., Hawtin P.G., and Hardcastle J.D. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ (Clinical Research Ed.) 307 6899 (1993) 285-289
77. Dube C., Rostom A., Lewin G., et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Annals of Internal Medicine 146 5 (2007) 365-375
78. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 146 5 (2007) 361-364
79. Flossmann E., and Rothwell P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369 9573 (2007) 1603-1613
80. Chakravarty E.F., Michaud K., and Wolfe F. Skin cancer, rheumatoid arthritis, tumor necrosis factor inhibitors. The Journal of Rheumatology 32 11 (2005) 2130-2135
81. Atroshi I., Gummesson C., Johnsson R., et al. Prevalence of carpal tunnel syndrome in a general population. The Journal of the American Medical Association 282 2 (1999) 153-158
82. Wolfe F., Caplan L., and Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scandinavian Journal of Rheumatology (2007)
83. Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest 93 1 (1988) 114-118
84. Hubbard R., and Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 41 6 (2002) 676-679
85. Turner-Warwick M., Lebowitz M., Burrows B., and Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35 7 (1980) 496-499
86. Atkins S.R., Matteson E.L., Myers J.L., et al. Morphological and quantitative assessment of mast cells in rheumatoid arthritis associated non-specific interstitial pneumonia and usual interstitial pneumonia. Annals of the Rheumatic Diseases 65 5 (2006) 677-680
87. Tanaka N., Kim J.S., Newell J.D., et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 232 1 (2004) 81-91
88. Scott D.L., Bradby G.V., Aitman T.J., et al. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Annals of the Rheumatic Diseases 40 2 (1981) 136-141
89. Evans R.B., Ettensohn D.B., Fawaz-Estrup F., et al. Gold lung: recent developments in pathogenesis, diagnosis, therapy. Seminars in Arthritis and Rheumatism 16 3 (1987) 196-205
90. Soler M.J., Barroso E., Aranda F.I., et al. Fatal, gold-induced pneumonitis. Rheumatology International 23 4 (2003) 207-210
91. Kay A. European League against rheumatism study of adverse reactions to D-penicillamine. British Journal of Rheumatology 25 2 (1986) 193-198
92. Shettar S.P., Chattopadhyay C., Wolstenholme R.J., and Swinson D.R. Diffuse alveolitis on a small dose of penicillamine. British Journal of Rheumatology 23 3 (1984) 220-224
93. Wolfe F., Schurle D.R., Lin J.J., et al. Upper and lower airway disease in penicillamine treated patients with rheumatoid arthritis. The Journal of Rheumatology 10 3 (1983) 406-410
94. Ulubas B., Sahin G., Ozer C., et al. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clinical Rheumatology 23 3 (2004) 249-251
95. Hamadeh M.A., Atkinson J., and Smith L.J. Sulfasalazine-induced pulmonary disease. Chest 101 4 (1992) 1033-1037
96. Timmer R., Duurkens V.A., and van Hees P.A. Sulphasalazine-induced eosinophilic pneumonia. The Netherlands Journal of Medicine 41 3-4 (1992) 153-157
97. Alarcon G.S., Kremer J.M., Macaluso M., et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Annals of Internal Medicine 127 5 (1997) 356-364
98. Cannon G.W. Methotrexate pulmonary toxicity. Rheumatic Diseases Clinics of North America 23 4 (1997) 917-937
99. Carroll G.J., Thomas R., Phatouros C.C., et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. The Journal of Rheumatology 21 1 (1994) 51-54
100. Rosenow III E.C. Drug-induced pulmonary disease. Disease-A-Month 40 5 (1994) 253-310
101. Leduc D., De Vuyst P., Lheureux P., et al. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 104 5 (1993) 1620-1623
102. Green L., Schattner A., and Berkenstadt H. Severe reversible interstitial pneumonitis induced by low dose methotrexate: report of a case and review of the literature. The Journal of Rheumatology 15 1 (1988) 110-112
103. Cannon G.W., Ward J.R., Clegg D.O., et al. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis and Rheumatism 26 10 (1983) 1269-1274
104. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 363 9407 (2004) 461
105. Scott D.L. Interstitial lung disease and disease modifying anti-rheumatic drugs. Lancet 363 9416 (2004) 1239-1240
106. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scandinavian Journal of Rheumatology 33 4 (2004) 276-277
107. Kramer N., Chuzhin Y., Kaufman L.D., et al. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis and Rheumatism 47 6 (2002) 670-671
108. Courtney P.A., Alderdice J., and Whitehead E.M. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis and Rheumatism 49 4 (2003) 617 author reply 617-8
109. Ostor A.J., Chilvers E.R., Somerville M.F., et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. The Journal of Rheumatology 33 3 (2006) 622-628
110. Saravanan V., and Kelly C.A. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 43 2 (2004) 143-147
111. Committee on safety of medicines. Methotrexate and pneumonitis. 5. Medicines and Healthcare products Regulatory Agency; 2003.
112. Kremer J.M., and Cannon G.W. Benefit/risk of leflunomide in rheumatoid arthritis. Clinical and Experimental Rheumatology 22 5 Suppl. 35 (2004) S95-S100
113. Roberts M.A., Andrews G.R., and Caird F.I. Skinfold thickness on the dorsum of the hand in the elderly. Age and Ageing 4 1 (1975) 8-15
114. Bendor R. Arthritis and I. Annals of Internal Medicine 131 2 (1999) 150-152
115. Douglas K.M., Ladoyanni E., Treharne G.J., et al. Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions. Annals of the Rheumatic Diseases 65 10 (2006) 1341-1345
116. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. The New England Journal of Medicine 352 13 (2005) 1293-1304
117. Da Silva J.A., Jacobs J.W., Kirwan J.R., et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Annals of the Rheumatic Diseases 65 3 (2006) 285-293
118. Klein B.E., Klein R., and Lee K.E. Incidence of age-related cataract: the Beaver Dam Eye Study. Archives of Ophthalmology 116 2 (1998) 219-225
119. Klein B.E., Klein R., and Linton K.L. Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study. Ophthalmology 99 4 (1992) 546-552
120. Garner S.E., Fidan D.D., Frankish R.R., et al. Rofecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews 1 (2005) CD003685
121. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. The New England Journal of Medicine 340 24 (1999) 1888-1899
122. Simon L.S., Weaver A.L., Graham D.Y., et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. The Journal of the American Medical Association 282 20 (1999) 1921-1928
123. Emery P., Zeidler H., Kvien T.K., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354 9196 (1999) 2106-2111
124. Goldstein J.L., Silverstein F.E., Agrawal N.M., et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. The American Journal of Gastroenterology 95 7 (2000) 1681-1690
125. Langman M.J., Jensen D.M., Watson D.J., et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. The Journal of the American Medical Association 282 20 (1999) 1929-1933
126. MacDonald T.M., Morant S.V., Robinson G.C., et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ (Clinical Research Ed.) 315 7119 (1997) 1333-1337
127. Lanza L.L., Walker A.M., Bortnichak E.A., and Dreyer N.A. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Archives of Internal Medicine 155 13 (1995) 1371-1377
128. Tenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Canadian Journal of Gastroenterology 13 2 (1999) 119-122
129. Langman M.J., Brooks P., Hawkey C.J., et al. Non-steroid anti-inflammatory drug associated ulcer: epidemiology, causation and treatment. European Journal of Gastroenterology & Hepatology 6 5 (1991) 442-449
130. Garcia Rodriguez L.A., and Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, combinations of these agents. Arthritis Research 3 2 (2001) 98-101
131. Simon L.S., Hatoum H.T., Bittman R.M., et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Family Medicine 28 3 (1996) 204-210
132. Hayllar J., Smith T., Macpherson A., et al. Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease-modifying antirheumatic drugs. Arthritis and Rheumatism 37 8 (1994) 1146-1150
133. Bjarnason I., Hayllar J., MacPherson A.J., and Russell A.S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104 6 (1993) 1832-1847
134. Mpofu S., Mpofu C.M., Hutchinson D., et al. Steroids, non-steroidal anti-inflammatory drugs, sigmoid diverticular abscess perforation in rheumatic conditions. Annals of the Rheumatic Diseases 63 5 (2004) 588-590
135. Hutchinson D., and Lynch M. Sigmoid diverticular abscess perforation in 2 patients with rheumatoid arthritis treated with high dose corticosteroids. A cautionary tale. The Journal of Rheumatology 28 8 (2001) 1935-1936
136. Myllykangas-Luosujarvi R. Diverticulosis-a primary cause of life-threatening complications in rheumatoid arthritis. Clinical and Experimental Rheumatology 13 1 (1995) 79-82
137. Laine L., Connors L.G., Reicin A., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124 2 (2003) 288-292
138. World Health Organization. Nutritional anemias: report of a WHO scientific group (1968), World Health Organization, Geneva, Switzerland
139. Wolfe F., and Michaud K. Anemia and renal function in patients with rheumatoid arthritis. The Journal of Rheumatology 33 8 (2006) 1516-1522
140. Franklin J., Lunt M., Bunn D., et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Annals of the Rheumatic Diseases 66 3 (2007) 308-312
141. Symmons D.P. Mortality in rheumatoid arthritis. British Journal of Rheumatology 27 supplement 1 (1988) 44-54
142. Prior P., Symmons D.P., Scott D.L., et al. Cause of death in rheumatoid arthritis. British Journal of Rheumatology 23 2 (1984) 92-99
143. Allebeck P. Increased mortality in rheumatoid arthritis. Scandinavian Journal of Rheumatology 11 2 (1982) 81-86
144. Koota K., Isomaki H., and Mutru O. Death rate and causes of death in RA patients during a period of five years. Scandinavian Journal of Rheumatology 6 4 (1977) 241-244
145. Isomaki H.A., Mutru O., and Koota K. Death rate and causes of death in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 4 4 (1975) 205-208
146. Salliot C., Gossec L., Ruyssen-Witrand A., et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 46 2 (2007) 327-334
147. Wolfe F., Caplan L., and Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, anti-tumor necrosis factor therapy. Arthritis and Rheumatism 54 2 (2006) 628-634
148. Costenbader K.H., Glass R., Cui J., and Shadick N. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. The Journal of the American Medical Association 296 18 (2006) 2201 author reply 2203-4
149. Curtis J.R., Patkar N., Xie A., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis and Rheumatism 56 4 (2007) 1125-1133
150. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism 54 8 (2006) 2368-2376
151. Wolfe F., Michaud K., Anderson J., and Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis and Rheumatism 50 2 (2004) 372-379
152. Winthrop K.L., Siegel J.N., Jereb J., et al. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis and Rheumatism 52 10 (2005) 2968-2974
153. Askling J., Fored C.M., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis and Rheumatism 52 7 (2005) 1986-1992
154. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. The New England Journal of Medicine 345 15 (2001) 1098-1104
155. Jick S.S., Lieberman E.S., Rahman M.U., and Choi H.K. Glucocorticoid use, other associated factors, the risk of tuberculosis. Arthritis and Rheumatism 55 1 (2006) 19-26
156. Weisman M.H. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. The Journal of Rheumatology 65 supplement (2002) 33-38
157. Hyrich K.L., Silman A.J., Watson K.D., and Symmons D.P. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Annals of the Rheumatic Diseases 63 12 (2004) 1538-1543
158. Wolfe F., Michaud K., and Chakravarty E.F. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 45 11 (2006) 1370-1375
159. Hawley D.J., and Wolfe F. Depression is not more common in rheumatoid arthritis: a 10-year longitudinal study of 6153 patients with rheumatic disease. The Journal of Rheumatology 20 12 (1993) 2025-2031
160. Ang D.C., Choi H., Kroenke K., and Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. The Journal of Rheumatology 32 6 (2005) 1013-1019
161. Haugeberg G., Uhlig T., Falch J.A., et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis and Rheumatism 43 3 (2000) 522-530
162. van Staa T.P., Geusens P., Bijlsma J.W.J., et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis and Rheumatism 54 10 (2006) 3104-3112
163. Lane N.E., Pressman A.R., Star V.L., et al. Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. Journal of Bone and Mineral Research 10 2 (1995) 257-263
164. Kroger H., Honkanen R., Saarikoski S., and Alhava E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis-a population based study. Annals of the Rheumatic Diseases 53 1 (1994) 18-23
165. Sinigaglia L., Nervetti A., Mela Q., et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian study group on bone mass in rheumatoid arthritis. The Journal of Rheumatology 27 11 (2000) 2582-2589
166. Sinigaglia L., Varenna M., Girasole G., and Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheumatic Diseases Clinics of North America 32 4 (2006) 631-658
167. Solomon D.H., Katz J.N., Cabral D., et al. Osteoporosis management in patients with rheumatoid arthritis: evidence for improvement. Arthritis and Rheumatism 55 6 (2006) 873-877
168. Maradit-Kremers H., Crowson C.S., Nicola P.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis and Rheumatism 52 2 (2005) 402-411
169. Anker S.D., and Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. International Journal of Cardiology 86 2-3 (2002) 123-130
170. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 25 (2003) 3133-3140
171. Mann D.L., McMurray J.J.V., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 13 (2004) 1594-1602